RT Journal Article
SR Electronic
T1 Secondary Progressive Multiple Sclerosis
JF Neurology - Neuroimmunology Neuroinflammation
JO Neurol Neuroimmunol Neuroinflamm
FD Lippincott Williams & Wilkins
SP e200064
DO 10.1212/NXI.0000000000200064
VO 10
IS 1
A1 Tjalf Ziemssen
A1 Virender Bhan
A1 Jeremy Chataway
A1 Tanuja Chitnis
A1 Bruce Anthony Campbell Cree
A1 Eva Kubala Havrdova
A1 Ludwig Kappos
A1 Pierre Labauge
A1 Aaron Miller
A1 Jin Nakahara
A1 Celia Oreja-Guevara
A1 Jacqueline Palace
A1 Barry Singer
A1 Maria Trojano
A1 Ashwini Patil
A1 Benedict Rauser
A1 Thomas Hach
YR 2023
UL http://nn.neurology.org/content/10/1/e200064.abstract
AB Many challenges exist in the precise diagnosis and clinical management of secondary progressive multiple sclerosis (SPMS) because of the lack of definitive clinical, imaging, immunologic, or pathologic criteria that demarcate the transition from relapsing-remitting MS to SPMS. This review provides an overview of the diagnostic criteria/definition and the heterogeneity associated with different SPMS patient populations; it also emphasizes the importance of available prospective/retrospective tools to identify patients with SPMS earlier in the disease course so that approved disease-modifying therapies and nonpharmacological strategies will translate into better outcomes. Delivery of such interventions necessitates an evolving patient-clinician dialog within the context of a multidisciplinary team.ARR=annualized relapse rate; CDW=confirmed disability worsening; DMTs=disease-modifying therapies; DSP=Disease-Specific Programme; EDSS=Expanded Disability Status Scale; EU=European Union; GFAP=glial fibrillary acidic protein; IFN-β=interferon-beta; IQR=interquartile range; MS=multiple sclerosis; MSFC=MS functional composite; NA=North American; OCT=optical coherence tomography; PIRA=progression independent of relapse activity; PRO=patient-reported outcome; RCN=research collaboration network; RNFL=retinal fiber layer; RRMS=relapsing-remitting MS; SPMS=secondary progressive MS